Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viking Therapeutics, Inc. (NASDAQ: VKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances a clinical-stage pipeline in metabolic and endocrine disorders. Viking’s Form 8-K filings, for example, report material events such as quarterly financial results and top-line clinical data from trials of VK2735, the company’s dual GLP-1/GIP receptor agonist being developed for obesity and other metabolic conditions. One 8-K references a press release announcing financial results and a corporate update, while another notes top-line Phase 2 results from the oral tablet formulation of VK2735.
Through SEC reports such as 8-K, investors can track how Viking communicates progress in its Phase 3 VANQUISH program for subcutaneous VK2735, Phase 2 and earlier-stage work on oral VK2735, and development of VK2809 for lipid and liver disorders and VK0214 for X-linked adrenoleukodystrophy. These filings complement press releases that describe statistically significant weight loss outcomes, safety and tolerability profiles, and achievement of primary and secondary endpoints in key studies.
On Stock Titan, Viking’s SEC filings are paired with AI-powered tools that summarize and explain the contents of lengthy documents. Investors can quickly understand the implications of quarterly updates, clinical data disclosures, and other material events without reading every line of each filing. Real-time updates from EDGAR ensure that new 8-Ks and other forms appear promptly, while AI-generated highlights help users focus on items such as clinical trial milestones, pipeline strategy, and financial condition as reported by Viking Therapeutics in its official SEC submissions.
Viking Therapeutics is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026 at 8:00 a.m. Pacific Time. Holders of 115,893,943 common shares as of March 20, 2026 can vote on electing two Class II directors, ratifying CBIZ CPAs P.C. as auditor for 2026, and approving executive compensation on an advisory basis. The meeting will be held via live webcast and requires a quorum of at least 57,946,972 shares. The proxy statement also outlines board structure, committee responsibilities, director independence and an executive pay program that emphasizes performance-based equity and annual incentives.
The Vanguard Group filed an Amendment No. 3 to Schedule 13G reporting that it beneficially owns 0 shares of Viking Therapeutics Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or business divisions to report beneficial ownership separately.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's principal business address in Malvern, Pennsylvania.
Viking Therapeutics, Inc. reported that Chief Commercial Officer Neil William Aubuchon purchased common stock in the company. On this transaction date, he made an open-market purchase of 4,475 shares of common stock at $33.50 per share. Following this trade, he directly holds 4,475 shares of Viking Therapeutics common stock.
Viking Therapeutics outlines a broad late-stage pipeline for metabolic and endocrine diseases in its annual report. Lead obesity candidate VK2735, a dual GLP-1/GIP agonist, has moved into Phase 3 VANQUISH studies after Phase 2 data showed up to 14.7% mean weight loss over 13 weeks and up to 88% of patients achieving at least 10% weight reduction.
The oral tablet form of VK2735 delivered up to 12.2% weight loss versus 1.3% with placebo over 13 weeks, supporting planned Phase 3 oral studies. NASH/MASH candidate VK2809 produced robust 52‑week histology results, with NASH resolution in up to 75% of patients and ≥1‑stage fibrosis improvement in up to 57%, both outperforming placebo.
Viking also reports positive early data in rare disease program VK0214 for X‑ALD and muscle‑building agent VK5211, while securing large-scale VK2735 manufacturing through multi‑year CordenPharma agreements. As context, non‑affiliate equity was valued at $2,976,737,289 as of June 30, 2025, with 115,554,295 shares outstanding as of January 31, 2026.
Viking Therapeutics reported a much larger net loss for 2025 as it accelerated investment in its obesity pipeline, led by dual GLP‑1/GIP agonist VK2735. For 2025, the company recorded a net loss of $358.5 million, or $3.19 per share, versus a loss of $110.0 million, or $1.01 per share, in 2024. Research and development spending rose to $345.0 million from $101.6 million, reflecting extensive Phase 3 work on subcutaneous VK2735, positive Phase 2 oral VK2735 data, and broader pipeline progress. General and administrative costs were roughly flat at $48.4 million. As of December 31, 2025, Viking held $706 million in cash, cash equivalents and short‑term investments, which the company believes supports key upcoming milestones. Clinical highlights include ongoing Phase 3 VANQUISH trials for injectable VK2735 in obesity, plans to start Phase 3 for oral VK2735 in 3Q26, a fully enrolled VK2735 maintenance dosing study with data expected in 3Q26, and plans to file an IND for a novel amylin agonist in 1Q26.
Viking Therapeutics Chief Commercial Officer Neil William Aubuchon received a grant of stock options on common stock. The award covers 180,000 stock options with an exercise price of $31.76 per share, expiring on 01/12/2036.
According to the vesting terms, 25% of the options vest immediately, and an additional 25% vest on each one-year anniversary of the grant date over the next three years. After this grant, Aubuchon directly holds 180,000 derivative securities in the form of these options.
Viking Therapeutics, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Neil William Aubuchon, on a Form 3. The filing states that, at the time of this report, he does not beneficially own any Viking Therapeutics securities, either directly or indirectly. This is a standard disclosure required when an individual becomes an officer of a public company and establishes a baseline of reported ownership going forward.
Viking Therapeutics reported insider equity activity by its Chief Operating Officer. On January 2, 2026, the officer received 41,000 restricted stock units and an additional 32,049 shares from performance-based restricted stock units, both at $0 cost, increasing beneficial ownership. On the same date, the officer was also granted a stock option for 91,000 shares at an exercise price of $35.42 per share, vesting in equal annual installments over four years. On January 5, 2026, a total of 57,661 shares were automatically sold in multiple transactions at weighted-average prices between about $31.87 and $35.20 to cover tax withholding obligations tied to these vesting awards. Following these transactions, the officer beneficially owned 409,190 shares of Viking Therapeutics common stock.
Viking Therapeutics (VKTX) COO reported Form 4 activity. On October 27, 2025, 11,117 shares were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On October 28, 2025, 6,185 shares were sold at a weighted average price of $35.0027 to cover tax withholding related to the vesting.
Following these transactions, the executive directly beneficially owned 382,467 shares. The sales were executed in multiple trades between $34.69 and $35.40.